These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31216854)

  • 1. Neoadjuvant Hypertermic Isolated Limb Perfusion in Treatment of Undifferentiated Spindle Cell Sarcoma of Lower Limb with Achieved Complete Pathologic Response.
    Vočka M; Špaček M; Matějovský Z; Trnka J; Hodková G; Skibová D; Zogala D; Lindner J; Petruželka L
    Klin Onkol; 2019; 32(3):211-213. PubMed ID: 31216854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
    Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
    Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared.
    Cecchin D; Negri A; Frigo AC; Bui F; Zucchetta P; Bodanza V; Gregianin M; Campana LG; Rossi CR; Rastrelli M
    Eur J Surg Oncol; 2016 Dec; 42(12):1898-1905. PubMed ID: 27005884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
    Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
    Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
    Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
    Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Size-based clinical response evaluation is insufficient to assess clinical response of sarcomas treated with isolated limb perfusion with TNF-α and melphalan.
    Grabellus F; Stylianou E; Umutlu L; Sheu SY; Lehmann N; Taeger G; Lauenstein TC
    Ann Surg Oncol; 2012 Oct; 19(11):3375-85. PubMed ID: 22622472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor.
    Olieman AF; van Ginkel RJ; Hoekstra HJ; Mooyaart EL; Molenaar WM; Koops HS
    Ann Surg Oncol; 1997 Jan; 4(1):64-9. PubMed ID: 8985519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma.
    Olieman AF; Pras E; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):807-14. PubMed ID: 9531364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hyperthermic Isolated Limb Perfusion Combined with Tasonermin - a Perfusion Leakage Monitoring Technique].
    Trnka J; Špaček M; Šírová V; Mitáš P; Hodková G; Kubinyi J; Špunda R; Lindner J
    Klin Onkol; 2016; 29(5):375-379. PubMed ID: 27739318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
    Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
    Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas.
    Schraffordt Koops H; Eggermont AM; Liénard D; Kroon BB; Hoekstra HJ; Van Geel AN; Nieweg OE; Lejeune FJ
    Semin Surg Oncol; 1998; 14(3):210-4. PubMed ID: 9548603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isolated Perfusion of the Upper Extremity with TNF-α - Double Venous Cannulation].
    Špaček M; Mitáš P; Vočka M; Lacina L; Hodková G; Špunda R; Kodet O; Krajsová I; Petruželka L; Trnka J; Kubinyi J; Matějovský Z; Lambert L; Lindner J
    Klin Onkol; 2017; 30(3):213-219. PubMed ID: 28612619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
    Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
    Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma.
    Jakob J; von Rege I; Weiss C; Hohenberger P
    Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.